Extracorporeal membrane oxygenation (ECMO) therapy might be controversial when patients with advanced malignant disease develop heart or lung failure refractory to conventional management. Especially as for the hematological malignancy patients, the induction of ECMO therapy must be considered carefully, since it is often associated with bleeding complications or infectious diseases. Here, we report a case of life-threatening airway obstruction requiring ECMO. The trachea of the patient was narrowed by an anterior mediastinal tumor too highly to ventilate both lungs, so she had to be connected to venovenous-ECMO (VV-ECMO) before pathological examination and radical treatment were planned. During the intensive care with ECMO, she was diagnosed with malignant lymphoma and the chemotherapy was started. The chemotherapy brought such an immediate result that the trachea regained its patency and ECMO was disconnected 9 days after the initiation of the chemotherapy. Then, the patient was able to leave the intensive care unit with no sequelae. Central airway obstruction is a lifethreatening situation, in which prompt decisions are essential. On the other hand, if the airway is impaired by hematological malignancy, it might be generally challenging to consider ECMO
Introduction
It is challenging to induce extracorporeal membrane oxygenation (ECMO) in case of severe respiratory failure related to hematological malignancy because such patients are vulnerable to several life-threatening complications [1] [2] [3] . Here, we report the case of central airway obstruction caused by anterior mediastinal lymphoma successfully managed with venovenous-ECMO (VV-ECMO).
Case Report
A 45-year-old woman had had complaint of dyspnea for several days and visited another hospital. She presented remarkable stridor on auscultation, and she could not lay on her back due to difficulty in breathing. She was referred to our hospital and was intubated soon after arrival because she was considered to be in danger of airway obstruction. Chest X-ray and CT scans revealed that the trachea was compressed by an anterior mediastinal tumor (Fig. 1a, b) , and the subsequent bronchoscopy showed that the trachea was markedly narrowed just above the carina (Fig. 2) . It was possible to ventilate at that moment, though the airway was still narrowed distal to the endotracheal tube. She was admitted to the intensive care unit and standard ventilator support was started. Then, the respiratory status and hemodynamics were stabilized temporarily. However, on the second day, the tidal volume decreased gradually and it became almost impossible to ventilate. Arterial blood gas analysis revealed a pH of 7.22, PaCO2 of 79 mm Hg, and PaO2 of 119 mm Hg, and the ventilatory support included pressure support of 15 cm H2O, positive end-expiratory pressure (PEEP) of 10 cmH2O, and FiO2 of 0.50. From then on, it was assumed that the tumor might be malignant, and there was no conclusive proof that we would be able to treat it radically. However, she was also considered to be on the verge of suffocation. So, we decided to immediately connect her to VV-ECMO. The ECMO was initially set as follows: blood flow 3.5 L/min and sweep gas flow 5.0 L/min (FiO2 0.70). It was unnecessary to adjust the ECMO during its running period. After the initiation of ECMO, the general status was stabilized, while the tidal volume finally decreased to approximately 30 mL. Pathological examination was implemented subsequently and she was diagnosed with large B-cell lymphoma. On the third day, prednisolone was administered and followed by R-CHOP regimen chemotherapy. The mediastinal tumor reduced promptly (Fig. 1c,  d ), and the trachea regained its patency dramatically (Fig. 2) . On the 10th day, it became possible to ventilate both lungs. When the sweep gas was stopped on trial off, arterial blood gas test showed a pH of 7.48, a PaCO2 of 34 mm Hg, and a ratio of partial pressure arterial oxygen and fraction of inspired oxygen (P/F ratio) of 300. Then ECMO was weaned on the 12th day. Throughout the period, partial thromboplastin time (PTT) and activated clotting time (ACT) had been maintained 48-62 s and 150-180 s, respectively. Platelet counts decreased gradually, but it had never been below 8 × 10 4 /μL. Furthermore, no complication such as bleeding and infection occurred. After the discontinuation of ECMO, her respiratory status had been still stable, and arterial blood gas test showed a pH of 7.44, PaCO2 of 39 mm Hg, and a P/F ratio of 430. She was extubated on the 16th day and discharged to the general ward on the 19th day without any sequelae. Chemotherapy was continued and she was discharged on the 40th day. Several courses of chemotherapy were followed. For the time being, she regularly attends a hematologist at our hospital and has been free from airway obstruction and a relapse so far.
Discussion
Central airway obstruction is a life-threatening pathology. The most common cause is direct extension from an adjacent tumor, such as bronchogenic carcinoma, esophageal carcinoma, and thyroid carcinoma. In addition, mediastinal tumor or nonmalignant etiologies are other possible causes [4] . It is reasonable that symptoms related to airway obstruction are in proportion to the extent of stenosis. However, it is also reported that patients do not show any symptom until the trachea is significantly narrowed to less than 8 mm. Then, once the lumen is less than 5 mm, symptoms present also at rest [4] . In this case, the narrowest diameter of the trachea was about 4 mm, which was just above the carina. That was narrow enough to cause dyspnea.
For patients with central airway obstruction, no matter what the cause is, securing the airway is essential. Especially in unstable patients, it might be challenging and should be accomplished by the most experienced physician. The strategy differs depending on the location and the extent of stenosis. Proximal airway obstruction simply requires tracheal intubation or tracheostomy. However, in the case of more distal obstruction, tracheal intubation might not be sufficient for ventilation. In such situations, ECMO is assumed to be used as a bridge until the procedures leading to definitive airway security are implemented [5, 6] .
ECMO is a remedy against severe heart or lung failure refractory to conventional management [7, 8] . Respiratory ECMO was initiated for neonates and pediatrics in the 1970's, and recently it has become widespread for adult patients through the publication of the CESAR trial [8] or the successful experiences of managing the influenza H1N1 pandemic. It is often the case that respiratory ECMO is used for patients with oxygenation or ventilation failure, such as severe ARDS [7] , and on the other hand, airway obstruction is relatively uncommon as an indication of ECMO.
Previous studies reported that ECMO should be applied carefully for hematological malignancy patients. Gow et al. [1] analyzed the data from the ELSO Registry and concluded that survival is decreased among adult patients with cancer compared with those without cancer. Moreover, the development of infections was considered an indicator for poor prognosis. Wohlfarth et al. [2] reported the case series of hematological malignancy patients managed with ECMO and concluded that ECMO was feasible in this population as well. However, it was also stated that these patients were at increased risk for severe bleeding events. Kang et al. [9] reported that case series of hematological malignancies supported by ECMO and bleeding events were not significantly more frequent in those patients than in immunocompetent patients. Thus, hematological malignancy patients have several risks related to ECMO management such as bleeding and infection. In order to manage successfully, it seems essential to weigh the risks appropriately and to avoid these complications. The reason why we could manage this case without any complication might be that chemotherapy brought an immediate result and ECMO could be disconnected before WBC nadir, which made us avoid the risks of bleeding or infection (Fig. 2) . Regarding the indication of ECMO for hematological malignancy patients, physicians have to consider it carefully, but do not have to regard it as a contraindication. According to the ELSO guidelines, most contraindications are relative, balancing the risks of the procedure against the potential benefits [10] . As a matter of course, in the case of imminent suffocation like our case, it is inevitable to initiate ECMO to save life.
In conclusion, we experienced a case of airway obstruction related to malignant lymphoma successfully managed with VV-ECMO. ECMO can be a treatment choice also for hematological malignancy patients, but physicians should pay careful attention to hemorrhagic complications and the development of infection. The clinical course during ICU stay and bronchoscopic findings on days 2 and 14 (upper 2 photographs). Chemotherapy brought an immediate result and ECMO was disconnected before WBC nadir. The value of LDH decreased dramatically, which was correlated with the reduction of the tumor.
